Tested Applications
| Positive WB detected in | HEK-293 cells, HeLa cells, U2OS cells, Jurkat cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
27242-1-AP targets Cyclin A2 in WB, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag25666 Product name: Recombinant human Cyclin A2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 405-432 aa of BC104783 Sequence: AQQSIREKYKNSKYHGVSLLNPPETLNL Predict reactive species |
| Full Name | cyclin A2 |
| Calculated Molecular Weight | 432 aa, 49 kDa |
| Observed Molecular Weight | 49 kDa |
| GenBank Accession Number | BC104783 |
| Gene Symbol | Cyclin A2 |
| Gene ID (NCBI) | 890 |
| RRID | AB_2880815 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P20248 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for Cyclin A2 antibody 27242-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The Cyclin A2 Polyclonal antibody (Cat# 27242-1-AP) has 6 total citations. These publications appear in Cancer Letters, International Journal of Molecular Medicine, Biomedicine & Pharmacotherapy, Oncogenesis, Cancer Science, and Biochemical and Biophysical Research Communications. The cited research spans oncology fields including colon cancer, colorectal cancer, lung adenocarcinoma, esophageal cancer, and hepatocellular carcinoma, with applications focused on cell senescence, mitophagy, signaling pathway inactivation, and prognostic biomarker development. All citations used the antibody for Western blot in human samples.
| Species | Application | Title |
|---|---|---|
Int J Mol Med Morusin inhibits the growth of human colorectal cancer HCT116‑derived sphere‑forming cells via the inactivation of Akt pathway. | ||
Biomed Pharmacother Deapioplatycodin D promotes cell senescence induced by P21 through the mediation of incomplete mitophagy via BNIP3L | ||
Oncogenesis CENPF (+) cancer cells promote malignant progression of early-stage TP53 mutant lung adenocarcinoma | ||
Cancer Sci Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer. | ||
Biochem Biophys Res Commun Constructing and validating pan-apoptosis-related features for predicting prognosis and immunotherapy response in hepatocellular carcinoma |





